Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Coupling object between CB and biological active peptide or immunoglobhulin or immunological activity original as well as medication usage

An immunoglobulin and biologically active peptide technology, applied in the field of compositions containing the same, can solve the problems of unobserved CB-GM1 receptor-mediated cell or nervous system diseases, influence on brain function, side effects and the like

Inactive Publication Date: 2003-10-08
万选才 +1
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Disadvantages of this technology: First, the systemic menstrual blood administration is not targeted, and it involves the whole brain and spinal cord, and the multifunctional neurotrophic factor is likely to have side effects in this case (such as: someone reported that BDNF may induce epilepsy) and second, antibodies against the transporter block the normal function of the transporter, potentially affecting brain function
All three types have relatively large surgical trauma and cannot be used for long-term or repeated use
But he has never been involved nor observed that CB-GM1 receptors mediate cellular or neurological disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coupling object between CB and biological active peptide or immunoglobhulin or immunological activity original as well as medication usage
  • Coupling object between CB and biological active peptide or immunoglobhulin or immunological activity original as well as medication usage
  • Coupling object between CB and biological active peptide or immunoglobhulin or immunological activity original as well as medication usage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment preparation Embodiment 1

[0060] EXAMPLES Preparative Example 1: Glutaraldehyde GA Conjugation of CB-IgG [Rabbit Anti-Substance P]

[0061] CB [pentamer molecular weight 45-50kDa, List Ltd., US] 3.0 mg dissolved in 1.25% GA [Sigma, used for electron microscope specimens] 1 ml, 0.1 M sodium phosphate (pH6.5) at room temperature overnight [compared Low pH can prevent self-coupling of lysine amino group in CB]; separated activated CB and unlinked glutaraldehyde ( Or pass through the column and dialyze in 0.15M NaCl to remove unlinked glutaraldehyde); use a microporous membrane to concentrate the CB component (molecular weight 45-50kDa) of the column solution to about 1ml.

[0062] Use 1M carbonate buffer (pH9.5) to adjust the pH of the concentrated activated CB to 9.5, add 9.0mg of rabbit anti-substance P IgG (molecular weight 150kDa) dissolved in 1M carbonate buffer (pH9.5) 1ml , reacted with activated CB for 24 hours at a low temperature of 4 degrees; the Sephadex G-200 gel column (1.6 × 90cm) was used...

preparation Embodiment 2

[0062] Use 1M carbonate buffer (pH9.5) to adjust the pH of the concentrated activated CB to 9.5, add 9.0mg of rabbit anti-substance P IgG (molecular weight 150kDa) dissolved in 1M carbonate buffer (pH9.5) 1ml , reacted with activated CB for 24 hours at a low temperature of 4 degrees; the Sephadex G-200 gel column (1.6 × 90cm) was used to separate the combined state (molecular weight 200kDa) and unbound components; concentrated and stabilized (adding lysine to make the composition 0.1M). Preparation Example 2: GA Coupling of CB-NGF

[0063] CB [molecular weight 45-50kDa, List Ltd., US] 4 mg dissolved in 1.25% GA [Sigma, used for electron microscope specimens] 1 ml, 0.1 M sodium phosphate (pH6.5) at room temperature overnight [lower pH can prevent The amino group of lysine in CB is self-coupling]; the activated CB is separated from unconnected glutaraldehyde (or not passed through the column) by Sephadex G-25 column gel column (40×0.9cm, passed through the column with 0.15M NaC...

preparation Embodiment 3

[0064] Use 1M carbonate buffer (pH9.5) to adjust the pH of the concentrated activated CB to 9.5, add NGF (betaNGF, 4mg two chains, molecular weight 26.0kDa, Sigma, N8133) 2.0mg dissolved in 1M carbonate buffer Solution (pH9.5) 1ml, reacted with activated CB for 24 hours at a low temperature of 4 degrees; separated the combined state (molecular weight 80kDa) and unbound components by Sephadex G-200 gel column (1.6×90cm); concentrated and stabilized ( Add lysine to make 0.1M). Preparation Example 3: Disulfide Bond S-S Coupling Process of CB-NGF

[0065] Dissolve 2.0mg of NGF (beta NGF, two chains, molecular weight 26.0kDa, Sigma, N8133) in 1ml, 1M carbonate buffer (pH8.5), slowly add 6.0mg / ml of citraconic anhydride (citric anhydride) , Sigma, US), placed at room temperature for 1 hour to block free amino groups; separated citric anhydride and NGF peptide with G10 gel column. Add 20 mg of EDC to 2.0 mg / 2 ml of NGF to act on the carboxyl group, first adjust the pH to 5, then ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A choleragen subunit B (CB) used as ligand / carrier, the conjugate of the bioactive polypeptide and immunoglobulin or immunoreactive source, which has the therapeutic action to encephalomyelopathy or cerebrorachidian injury, the compound composition containing said conjugate and medicinal additive, and the preparing process able to keep the bioactivity of said conjugate are disclosed. A delivery system (DS) with nerve receptor mediated endocytosis (RME) is created.

Description

technical field [0001] The invention relates to a conjugate of cholerogen B subunit as ligand / carrier and biologically active polypeptide, immunoglobulin or immune active agent, its medical use and preparation method, and the composition containing it. Background technique [0002] Traditional pharmaceutical drug delivery systems are basically 'blood routed delivery system': whether it is the 'gastrointestinal blood circulation' that was first taken orally in history, or various injections (i.m, i.v., etc.) )' into the blood circulation through the intramuscular microvessels or directly into the blood vessels'. Traditional research on pharmaceutical preparations that cannot penetrate the blood-brain barrier (BBB) ​​also focuses on the 'menstrual blood route', focuses on the BBB itself, and tries to change the preparation to make it easier to pass through the BBB of brain vascular endothelial cells. For example: changing the preparation to make it more fat-soluble, changing ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61K38/18A61K39/12A61K39/395A61K47/46A61P25/00A61P25/06A61P25/16A61P25/28
Inventor 万选才李小银
Owner 万选才
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com